OBJECTIVE: The aim of this pilot study was to examine the pharmacokinetics of atazanavir (ATV) when given in combination with amprenavir (APV) or saquinavir hard-gel capsules (SQV) to human immunodeficiency virus (HIV)-positive patients. METHODS: Included in the study were 34 HIV-infected patients enrolled in the ATV Early Access Program, who were treated with unboosted ATV alone (group 1) or with the double protease inhibitor combinations, ATV plus APV (group 2) or ATV plus SQV (group 3). ATV was given at a daily dose of 400 mg q.d. with the morning meal with SQV 1200 mg per day or APV 1200 mg per day. Serial blood samples for steady-state ATV pharmacokinetics were collected before the morning dose and at 1, 2, 3, 6, 8 and 24 h post-dosing. ATV plasma concentrations were measured using a high-performance liquid chromatography method with ultraviolet detection. RESULTS: Of the patients, 12 received ATV as a single protease inhibitor; 12 received ATV in combination with APV; and 10 in combination with SQV. Geometric mean (coefficient of variation) ATV C(trough) was 110 ng/ml (2.38), 86 ng/ml (0.84) and 149 ng/ml (2.01) in groups 1, 2 and 3, respectively. ATV C(trough) in both double protease inhibitor combination regimens was not significantly different from that as a single protease inhibitor [geometric mean ratio (GMR): 0.77; 95% confidence interval (CI): 0.38-1.58, P=not significant for group 2 versus group 1 and 1.34, 0.40-4.49, P=not significant, for group 3 versus group 1). Patients treated with ATV plus APV had a 40.2% lower ATV C(max) and a 30.8% smaller ATV AUC than the reference group treated with unboosted ATV alone: both these differences were statistically significant (GMR, 95% CI: 0.59, 0.41-0.85, P=0.005 and 0.69, 0.48-0.99, P=0.056, respectively). No difference was observed for either C(max) or AUC between the group treated with ATV plus SQV and the reference group (GMR, 95% CI: 0.78, 0.47-1.30, P=not significant and 1.24, 0.73-2.10, P=not significant, respectively). CONCLUSION: ATV pharmacokinetics does not seem to be influenced by the concomitant administration of SQV, whereas APV significantly lowers plasma ATV levels.
OBJECTIVE: The aim of this pilot study was to examine the pharmacokinetics of atazanavir (ATV) when given in combination with amprenavir (APV) or saquinavir hard-gel capsules (SQV) to human immunodeficiency virus (HIV)-positivepatients. METHODS: Included in the study were 34 HIV-infectedpatients enrolled in the ATV Early Access Program, who were treated with unboosted ATV alone (group 1) or with the double protease inhibitor combinations, ATV plus APV (group 2) or ATV plus SQV (group 3). ATV was given at a daily dose of 400 mg q.d. with the morning meal with SQV 1200 mg per day or APV 1200 mg per day. Serial blood samples for steady-state ATV pharmacokinetics were collected before the morning dose and at 1, 2, 3, 6, 8 and 24 h post-dosing. ATV plasma concentrations were measured using a high-performance liquid chromatography method with ultraviolet detection. RESULTS: Of the patients, 12 received ATV as a single protease inhibitor; 12 received ATV in combination with APV; and 10 in combination with SQV. Geometric mean (coefficient of variation) ATV C(trough) was 110 ng/ml (2.38), 86 ng/ml (0.84) and 149 ng/ml (2.01) in groups 1, 2 and 3, respectively. ATV C(trough) in both double protease inhibitor combination regimens was not significantly different from that as a single protease inhibitor [geometric mean ratio (GMR): 0.77; 95% confidence interval (CI): 0.38-1.58, P=not significant for group 2 versus group 1 and 1.34, 0.40-4.49, P=not significant, for group 3 versus group 1). Patients treated with ATV plus APV had a 40.2% lower ATV C(max) and a 30.8% smaller ATV AUC than the reference group treated with unboosted ATV alone: both these differences were statistically significant (GMR, 95% CI: 0.59, 0.41-0.85, P=0.005 and 0.69, 0.48-0.99, P=0.056, respectively). No difference was observed for either C(max) or AUC between the group treated with ATV plus SQV and the reference group (GMR, 95% CI: 0.78, 0.47-1.30, P=not significant and 1.24, 0.73-2.10, P=not significant, respectively). CONCLUSION:ATV pharmacokinetics does not seem to be influenced by the concomitant administration of SQV, whereas APV significantly lowers plasma ATV levels.
Authors: Charles J L la Porte; Jan-Christian Wasmuth; Katrin Schneider; Jürgen K Rockstroh; David M Burger Journal: AIDS Date: 2003-07-25 Impact factor: 4.177
Authors: Andrea De Luca; Francesco Baldini; Antonella Cingolani; Simona Di Giambenedetto; Richard M Hoetelmans; Roberto Cauda Journal: J Acquir Immune Defic Syndr Date: 2004-04-01 Impact factor: 3.731
Authors: Amanda H Corbett; Joseph J Eron; Susan A Fiscus; Naser L Rezk; Angela D M Kashuba Journal: J Acquir Immune Defic Syndr Date: 2004-08-01 Impact factor: 3.731
Authors: Marc Pfister; Line Labbé; Jian-Feng Lu; Scott M Hammer; John Mellors; Kara K Bennett; Susan Rosenkranz; Lewis B Sheiner Journal: Clin Pharmacol Ther Date: 2002-08 Impact factor: 6.875
Authors: Nils von Hentig; Axel Müller; Carsten Rottmann; Timo Wolf; Thomas Lutz; Stephan Klauke; Michael Kurowski; Bruno Oertel; Brenda Dauer; Sebastian Harder; Schlomo Staszewski Journal: Antimicrob Agents Chemother Date: 2007-02-12 Impact factor: 5.191
Authors: Nils von Hentig; Pavel Kaykhin; Christoph Stephan; Errol Babacan; Martin Stürmer; Schlomo Staszewski; Jörn Lötsch Journal: Antimicrob Agents Chemother Date: 2008-04-14 Impact factor: 5.191
Authors: Laura Dickinson; Marta Boffito; David Back; Laura Waters; Laura Else; Geraint Davies; Saye Khoo; Anton Pozniak; Leon Aarons Journal: J Antimicrob Chemother Date: 2009-03-28 Impact factor: 5.790